RAPP - CIK 0002012593
The table below shows Rapport Therapeutics, Inc.'s balance sheet by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $78.06M | $251.36M | $55.07M | $57.60M | $39.31M | $110.16M |
| Short-term investments | $398.73M | $261.67M | $205.38M | $227.78M | $281.35M | $225.97M |
| Receivables | $58.00K | - | - | - | - | - |
| Inventory | - | - | - | - | - | - |
| Total current assets |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $484.69M |
| $520.66M |
| $270.24M |
| $290.97M |
| $325.94M |
| $340.67M |
| Property, plant & equipment | $2.52M | $3.12M | $3.17M | $3.40M | $3.41M | $3.47M |
| Goodwill | - | - | - | - | - | - |
| Total assets | $497.60M | $535.32M | $285.50M | $302.05M | $331.14M | $346.10M |
| Accounts payable | $6.56M | $3.23M | $3.18M | $2.14M | $1.32M | $1.88M |
| Total current liabilities | $17.90M | $14.32M | $11.88M | $9.38M | $7.10M | $8.10M |
| Long-term debt | - | - | - | - | - | - |
| Total liabilities | $26.09M | $23.71M | $21.98M | $16.22M | $8.03M | $9.21M |
| Retained earnings | -$255.09M | -$201.47M | -$174.54M | -$147.81M | -$103.77M | -$86.23M |
| Total equity | $471.51M | $511.62M | $263.51M | $285.84M | $323.11M | $336.89M |